You'll have to read the 5page download, the abstract tells you nothing. 41 references in the paper so it might be good. This is where a great stroke association would be summarizing every research paper on stroke for relevance to helping survivors. Rather than the 10 million yearly stroke survivors all having to look for valid stroke recovery protocols. Or the hundreds of thousands of doctors and therapists looking for those same recovery protocols. And our stroke boards of directors can't see the stupidity of that.
Mesenchymal stromal cell therapy in ischemic stroke
Authors Zhang Y, Deng H, Pan C, Hu Y, Wu Q, Liu N, Tang ZP
Received 16 August 2016
Accepted for publication 12 October 2016
Published 10 November 2016 Volume 2016:4 Pages 79—83
DOI https://doi.org/10.2147/JN.S119874
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Hongyun Huang
Received 16 August 2016
Accepted for publication 12 October 2016
Published 10 November 2016 Volume 2016:4 Pages 79—83
DOI https://doi.org/10.2147/JN.S119874
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Hongyun Huang
Ye Zhang, Hong Deng, Chao Pan, Yang Hu, Qian Wu, Na Liu, Zhouping Tang
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Abstract: Stroke is a clinical disease with high incidence, high disability rate, and high mortality. But effective and safe therapy for stroke remains limited. Adult mesenchymal stromal cells (MSCs) perform a variety of therapeutic functions. MSC delivery improves neurological outcomes in ischemic stroke models via neurorestorative and neuroprotective effects such as angiogenic effects, promoting endogenous proliferation, and reducing apoptosis and inflammation. MSC secretome also showed powerful therapeutic effects as a cell-based therapy in animal experiments. Several clinical trials on MSC implantation via different routes have now been completed in patients with stroke. Although challenges such as immunogenicity of allo-MSCs and large-scale production strategies need to be overcome, MSCs can be considered as a promising potential therapy for ischemic stroke.
Full paper at link.
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
Abstract: Stroke is a clinical disease with high incidence, high disability rate, and high mortality. But effective and safe therapy for stroke remains limited. Adult mesenchymal stromal cells (MSCs) perform a variety of therapeutic functions. MSC delivery improves neurological outcomes in ischemic stroke models via neurorestorative and neuroprotective effects such as angiogenic effects, promoting endogenous proliferation, and reducing apoptosis and inflammation. MSC secretome also showed powerful therapeutic effects as a cell-based therapy in animal experiments. Several clinical trials on MSC implantation via different routes have now been completed in patients with stroke. Although challenges such as immunogenicity of allo-MSCs and large-scale production strategies need to be overcome, MSCs can be considered as a promising potential therapy for ischemic stroke.
Full paper at link.
No comments:
Post a Comment